Cargando…
Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction
OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particl...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Heart
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629948/ https://www.ncbi.nlm.nih.gov/pubmed/28642288 http://dx.doi.org/10.1136/heartjnl-2016-311018 |
_version_ | 1783269152813744128 |
---|---|
author | Stirrat, Colin G Alam, Shirjel R MacGillivray, Thomas J Gray, Calum D Dweck, Marc R Raftis, Jennifer Jenkins, William SA Wallace, William A Pessotto, Renzo Lim, Kelvin HH Mirsadraee, Saeed Henriksen, Peter A Semple, Scott IK Newby, David E |
author_facet | Stirrat, Colin G Alam, Shirjel R MacGillivray, Thomas J Gray, Calum D Dweck, Marc R Raftis, Jennifer Jenkins, William SA Wallace, William A Pessotto, Renzo Lim, Kelvin HH Mirsadraee, Saeed Henriksen, Peter A Semple, Scott IK Newby, David E |
author_sort | Stirrat, Colin G |
collection | PubMed |
description | OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particles of iron oxide (USPIO)-enhanced MRI. METHODS: Thirty-one patients were recruited following acute MI and followed up for 3 months with repeated T2 and USPIO-enhanced T2*-mapping MRI. Regions of interest were categorised into infarct, peri-infarct and remote myocardial zones, and compared with control tissues. RESULTS: Following a single dose, USPIO enhancement was detected in the myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron and macrophages within the infarcted, but not the non-infarcted, myocardium. Following repeated doses, USPIO uptake in the infarct zone peaked at days 2–3, and greater USPIO uptake was detected in the infarct zone compared with remote myocardium until days 10–16 (p<0.05). In contrast, T2-defined myocardial oedema peaked at days 3–9 and remained increased in the infarct zone throughout the 3-month follow-up period (p<0.01). CONCLUSION: Myocardial macrophage activity can be detected using USPIO-enhanced MRI in the first 2 weeks following acute MI. This observed pattern of cellular inflammation is distinct, and provides complementary information to the more prolonged myocardial oedema detectable using T2 mapping. This imaging technique holds promise as a non-invasive method of assessing and monitoring myocardial cellular inflammation with potential application to diagnosis, risk stratification and assessment of novel anti-inflammatory therapeutic interventions. TRIAL REGISTRATION NUMBER: Trial registration number: 14663. Registered on UK Clinical Research Network (http://public.ukcrn.org.uk) and also ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02319278?term=DECIFER&rank=2). |
format | Online Article Text |
id | pubmed-5629948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Heart |
record_format | MEDLINE/PubMed |
spelling | pubmed-56299482017-10-11 Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction Stirrat, Colin G Alam, Shirjel R MacGillivray, Thomas J Gray, Calum D Dweck, Marc R Raftis, Jennifer Jenkins, William SA Wallace, William A Pessotto, Renzo Lim, Kelvin HH Mirsadraee, Saeed Henriksen, Peter A Semple, Scott IK Newby, David E Heart Special Populations OBJECTIVES: Macrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particles of iron oxide (USPIO)-enhanced MRI. METHODS: Thirty-one patients were recruited following acute MI and followed up for 3 months with repeated T2 and USPIO-enhanced T2*-mapping MRI. Regions of interest were categorised into infarct, peri-infarct and remote myocardial zones, and compared with control tissues. RESULTS: Following a single dose, USPIO enhancement was detected in the myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron and macrophages within the infarcted, but not the non-infarcted, myocardium. Following repeated doses, USPIO uptake in the infarct zone peaked at days 2–3, and greater USPIO uptake was detected in the infarct zone compared with remote myocardium until days 10–16 (p<0.05). In contrast, T2-defined myocardial oedema peaked at days 3–9 and remained increased in the infarct zone throughout the 3-month follow-up period (p<0.01). CONCLUSION: Myocardial macrophage activity can be detected using USPIO-enhanced MRI in the first 2 weeks following acute MI. This observed pattern of cellular inflammation is distinct, and provides complementary information to the more prolonged myocardial oedema detectable using T2 mapping. This imaging technique holds promise as a non-invasive method of assessing and monitoring myocardial cellular inflammation with potential application to diagnosis, risk stratification and assessment of novel anti-inflammatory therapeutic interventions. TRIAL REGISTRATION NUMBER: Trial registration number: 14663. Registered on UK Clinical Research Network (http://public.ukcrn.org.uk) and also ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02319278?term=DECIFER&rank=2). Heart 2017-10 2017-06-22 /pmc/articles/PMC5629948/ /pubmed/28642288 http://dx.doi.org/10.1136/heartjnl-2016-311018 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Special Populations Stirrat, Colin G Alam, Shirjel R MacGillivray, Thomas J Gray, Calum D Dweck, Marc R Raftis, Jennifer Jenkins, William SA Wallace, William A Pessotto, Renzo Lim, Kelvin HH Mirsadraee, Saeed Henriksen, Peter A Semple, Scott IK Newby, David E Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
title | Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
title_full | Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
title_fullStr | Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
title_full_unstemmed | Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
title_short | Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
title_sort | ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction |
topic | Special Populations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629948/ https://www.ncbi.nlm.nih.gov/pubmed/28642288 http://dx.doi.org/10.1136/heartjnl-2016-311018 |
work_keys_str_mv | AT stirratcoling ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT alamshirjelr ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT macgillivraythomasj ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT graycalumd ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT dweckmarcr ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT raftisjennifer ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT jenkinswilliamsa ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT wallacewilliama ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT pessottorenzo ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT limkelvinhh ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT mirsadraeesaeed ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT henriksenpetera ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT semplescottik ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction AT newbydavide ferumoxytolenhancedmagneticresonanceimagingassessinginflammationaftermyocardialinfarction |